A cellular protein, FGD3, boosts breast cancer chemotherapy, immunotherapy

Six researchers gather in a lab
A naturally occurring protein that tends to be expressed at higher levels in breast cancer cells boosts the effectiveness of some anticancer agents, including doxorubicin, one of the most widely used chemotherapies, and a preclinical drug known as ErSO, researchers report. The protein, FGD3,...

Unprecedented Compound Takes a Step Toward Breast Cancer Clinical Trials

Website_Image_ERSO__David_Shapiro__Paul_Hergenrother_(1).png
Estrogen receptor-positive breast cancer is the most common form of breast cancer, affecting approximately 75 percent of breast cancer patients. In advanced and metastatic form, it is lethal, claiming the lives of nearly 350,000 individuals annually. Presently, no drug is able to eradicate these...

Novel Compound May Block Certain Forms of Aggressive Cancer

Benita Katzenellenbogan and John Katzenellenbogen
University of Illinois scientists Benita Katzenellenbogen, Swanlund Professor of Molecular & Integrative Physiology, and John Katzenellenbogen, Swanlund Professor of Chemistry, have developed a new compound with efficacy in suppressing tumor initiation, progression, and metastasis of...